The U.S. Food and Drug Administration has approved marketing of software enabling clinicians to non-invasively evaluate blood flow in coronary arteries of patients showing symptoms of coronary artery disease.  

The software from Redwood City, Calif.-based from HeartFlow provides an estimate of fractional flow reserve (FFR)—clinical information to help determine the extent of a blockage in the heart or a coronary artery—using data from a computed tomography (CT) scan of the patient’s heart.

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access